Innoviva, Inc.

NasdaqGS INVA

Innoviva, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 73,750,750

Innoviva, Inc. Shares (Diluted, Weighted) is 73,750,750 for the Trailing 12 Months (TTM) ending September 30, 2024, a -5.17% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Innoviva, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 77,774,250, a -15.23% change year over year.
Innoviva, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 91,745,750, a -10.39% change year over year.
Innoviva, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 102,388,000, a -9.81% change year over year.
Innoviva, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 113,519,750, a 0.13% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGS: INVA

Innoviva, Inc.

CEO	Mr. Pavel Raifeld C.F.A.
IPO Date	Oct. 5, 2004
Location	United States
Headquarters	1350 Old Bayshore Highway
Employees	112
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Key trends

Past 5 years